With around 2,500 attendees, Barcelona hosted the most successful BIO Europe Spring conference in the history of the EBD’s partnering event. Southern Europe demonstrated its growth ambitions in the life sciences.
?? Dentons has announced the cooptation of Julien Le Guyader as partner in the Life Sciences Group of the Paris Office. Le Guyader has been a part of ?? Dentons since 2014.
https://european-biotechnology.com/wp-content/uploads/2024/04/julien-le-guyader.jpg472420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-03-21 16:52:392024-04-02 14:36:05Dentons: All about taxes
Scottish and Canadian researchers have identified a protein essential for the toxoplasmosis parasite to be transmitted. Targeting it might give rise to new treatments other parasitic diseases like malaria.
Belgian clinical-stage immunotherapy developer Asit biotech has appointed Gerd Zettlmeissl as its new Chairman of the Board. Zettlmeissl has been independent director of the company since 2011.
British inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-03-20 10:18:592017-03-20 10:18:59Pulmocide raises £25m in Series B round
The investment groups Q-Growth Fund and Biolty purchased the majority of the Valencian biotechnology company Institute of Genomic Medicine (Imegen) for €10m.
British Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellmedica.jpg363580Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-03-16 09:28:012017-03-16 09:28:01Cell Medica bags €68,8 in Series C
According to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277m.
Transgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer (NSCLC).
Belgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction.
BIO-Europe Spring: Southern growth ambitions
Latest NewsWith around 2,500 attendees, Barcelona hosted the most successful BIO Europe Spring conference in the history of the EBD’s partnering event. Southern Europe demonstrated its growth ambitions in the life sciences.
Dentons: All about taxes
AppointmentsToxoplasmosis: novel target to prevent transmission
Latest NewsScottish and Canadian researchers have identified a protein essential for the toxoplasmosis parasite to be transmitted. Targeting it might give rise to new treatments other parasitic diseases like malaria.
Asit biotech: Expertise in vaccines
AppointmentsPulmocide raises £25m in Series B round
Latest NewsBritish inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing.
Investors purchase Imegen
Latest NewsThe investment groups Q-Growth Fund and Biolty purchased the majority of the Valencian biotechnology company Institute of Genomic Medicine (Imegen) for €10m.
Cell Medica bags €68,8 in Series C
Latest NewsBritish Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection.
Avantium raised €103m in oversubscribed IPO
Latest NewsAccording to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277m.
NSCLC: Transgene launches cancer combo tests
Latest NewsTransgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer (NSCLC).
Allogenic stem cell transplant safe in heart infarction patients
Latest NewsBelgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction.